Healthcare economics is the study of how limited resources like money, staff, and equipment are allocated within healthcare systems to produce the best possible health outcomes. It sits at the intersection of medicine and economics, applying principles of efficiency and trade-offs to questions that affect everyone: How should a country spend its healthcare budget? Why do drug prices vary so wildly? Why does health insurance work differently from other markets? At its core, the field tries to maximize health outcomes with the resources available, or alternatively, find ways to achieve the same outcomes while spending less.
Why Healthcare Doesn’t Follow Normal Market Rules
Most economic models assume that buyers know what they’re purchasing, can compare options, and can walk away from a bad deal. Healthcare violates nearly all of these assumptions. In a landmark 1963 paper, economist Kenneth Arrow identified the root cause: uncertainty. You can’t predict when you’ll get sick, how severe it will be, or whether a treatment will work. That unpredictability makes healthcare fundamentally different from buying groceries or a car.
The information gap between doctors and patients creates another distortion. Your physician knows far more about the consequences and possibilities of treatment than you do, and both of you know it. This imbalance means patients can’t evaluate what they’re buying in the way a consumer normally would. You’re essentially trusting the seller to act in your interest, which is why medicine developed professional obligations and licensing requirements that don’t exist in most other industries. Delegation and trust become the social institutions that fill the gap where normal market forces can’t operate.
These aren’t minor quirks. They mean that standard supply-and-demand thinking often produces the wrong answers when applied to healthcare. A whole class of health-related risks simply can’t be insured or traded on open markets, which is why governments, professional norms, and regulation play a much larger role in healthcare than in most other sectors of the economy.
What Drives Demand for Healthcare
The biggest driver of healthcare demand is straightforward: people get sick and need treatment. But what makes people sick, and how much care they seek, depends on a web of factors. Genetics and biology create baseline needs, from inherited conditions to age-related decline. Individual behaviors like smoking, diet, and physical activity generate additional demand. Environmental factors, including pollution and workplace hazards, contribute as well.
Economists increasingly focus on social determinants of health: education level, income stability, neighborhood safety, access to nutritious food, and housing quality. These factors correlate strongly with how healthy a population is and, by extension, how much healthcare it consumes. A community with high poverty and poor housing will generate more demand for medical services than an affluent one, all else being equal. This is why healthcare economics can’t be separated from broader economic policy.
What Constrains Supply
Even when demand exists, supply doesn’t always meet it. Geographic distribution is a persistent problem. Rural areas have fewer specialty physicians and significantly fewer mental health providers than urban centers, and physician supply decreases steadily as rurality increases. Attracting and retaining doctors in these areas has proven difficult across regions.
Insurance creates another layer of constraint. Providers may refuse patients whose insurance they don’t accept, or whose reimbursement rates are too low to cover costs. Long wait times for appointments deter use even when providers technically exist in an area. Language barriers and physical accessibility of clinics further limit who can actually receive care. Supply in healthcare economics isn’t just about how many doctors exist. It’s about whether a specific patient can reach a specific provider at a specific time.
The Insurance Problem: Moral Hazard and Adverse Selection
Health insurance introduces two well-known economic distortions. Moral hazard is the tendency for insured people to use more healthcare than they would if paying out of pocket, since insurance reduces the cost they face at the point of service. Cost-sharing mechanisms like copays and deductibles are designed to counteract this by keeping some financial skin in the game.
Adverse selection is the opposite problem, viewed from the insurer’s side. People who expect to need more care are more likely to buy generous insurance plans, while healthier people gravitate toward cheaper, minimal coverage. This sorting drives up costs in comprehensive plans because the pool of enrollees is sicker than average. Research examining private insurance plans found that adverse selection accounted for 53% of the additional medical spending observed in the most generous plan compared to the least generous one. In practical terms, an individual enrolling in the most generous plan paid over $69 per month in extra premiums just to cover the higher expected costs of the sicker population that selected into that plan. The Affordable Care Act’s individual mandate was specifically designed to reduce this kind of sorting by bringing healthier people into the insurance pool.
How Economists Measure Value in Healthcare
Healthcare economics needs a way to compare very different treatments and interventions on the same scale. Two tools dominate this work. Quality-adjusted life years (QALYs) combine how long a treatment helps someone live with how good that life is. A year of perfect health equals one QALY; a year lived with significant disability counts as less. Disability-adjusted life years (DALYs) approach the same problem from the opposite direction, measuring how many years of healthy life are lost to illness or disability.
These metrics allow cost-effectiveness analysis: comparing the price of a treatment to the health gains it produces. A new cancer drug might extend life by two years but cost $200,000. A screening program might prevent disease in thousands of people for a fraction of that cost per person. Health economists use these comparisons to help policymakers decide where limited budgets will do the most good. The tools aren’t perfect, and debates about how to value a year of life are ongoing, but they provide a structured framework for decisions that would otherwise be made on intuition or political pressure alone.
How Providers Get Paid Changes What They Do
The traditional fee-for-service model pays doctors and hospitals for each test, visit, or procedure they perform. The economic incentive is clear: more services mean more revenue, regardless of whether additional services improve health. Value-based payment models flip this by tying reimbursement to patient outcomes and quality metrics rather than volume.
The difference shows up in measurable ways. A large-scale analysis of Medicare Advantage found that value-based models outperformed fee-for-service across all quality measures examined, with an average score difference of 6.7%. For specific conditions, the gaps were dramatic: blood glucose control was 25.5% better under value-based care, and blood pressure management was 23.3% better. Models where providers shared financial risk in both directions (earning more for good outcomes, losing revenue for poor ones) performed best of all. These findings have accelerated a shift across the U.S. healthcare system toward value-based arrangements, though the transition is slow and uneven.
The Economics of Drug Pricing
Pharmaceutical pricing sits at one of the most contentious intersections of healthcare and economics. Drug companies argue that high prices are necessary to recoup research and development costs and fund future innovation. But the actual R&D cost per new drug is remarkably uncertain, with estimates ranging from $648 million to $2.87 billion per approved medicine, and even higher in cancer treatment. This enormous range itself reflects a key economic problem: the pharmaceutical market is defined by information asymmetries, with companies holding much more precise knowledge of their actual costs, prices, and clinical data than buyers or regulators.
Research using economic experiments suggests the relationship between pricing and innovation is more nuanced than the industry narrative implies. When both drug prices and R&D costs were made transparent in experimental settings, prices dropped by 26% with no statistically significant decrease in willingness to invest in R&D. Making prices alone transparent (without R&D cost data) actually reduced R&D investment by nearly 17%, while doing nothing to lower prices. The implication is that transparency works only when it’s comprehensive, giving negotiators enough information to set prices that balance affordability with continued innovation.
How Much Countries Actually Spend
OECD countries allocated an estimated 9.3% of GDP to health in 2024, up from 2023 but still below the pandemic peak of 9.6% in 2020 and 2021. Before the pandemic, healthcare spending had held relatively steady at about 8.8% of GDP since 2013. The pandemic permanently ratcheted up spending levels, and no country has fully returned to its pre-2020 baseline. The United States remains a significant outlier, spending roughly twice the OECD average as a share of GDP without proportionally better health outcomes, a puzzle that healthcare economists have studied for decades.
These numbers matter because every percentage point of GDP directed toward healthcare is a percentage point not spent on education, infrastructure, or other public goods. Healthcare economics doesn’t just ask whether a treatment works. It asks whether the resources it consumes could produce more health, or more well-being, if spent differently. That question applies at every level, from a hospital deciding whether to buy a new MRI machine to a government deciding how to structure its entire health system.